New bladder cancer drug aims to match gold standard in major trial
Disease control
Recruiting now
This Phase 3 trial tests a new treatment called VERITY-BCG for people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG therapy before. The study compares VERITY-BCG to the standard BCG treatment (OncoTICE) to see if it works just as well…
Phase: PHASE3 • Sponsor: Verity Pharmaceuticals Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC